Results 131 to 140 of about 3,151,736 (215)

If commercial incentives are the engine, then conflicts of interest are the lubricant. [PDF]

Future Healthc J
van Tulleken C.
europepmc   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

The Evidence Driving Policy for the Implementation of Virtual Rehabilitation Is Riddled With Conflicts of Interest. [PDF]

Sports Health
Rhon DI, McDevitt A, Magel J, Donaldson MB.   +3 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Submission policy, peer-review and editorial board members: interesting conflicts and conflicts of interest

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2010
Søreide Kjetil, Ringdal Kjetil G, Lossius Hans   +2 more
doaj   +1 more source

Conflicts of Interest and Industry Influence in Randomized Controlled Trials in Hand Surgery: A Systematic Review. [PDF]

Rev Bras Ortop (Sao Paulo)
Guimarães GHDS, Santos RSS, Nakachima LR, Santos DRD, Belloti JC, Moraes VY.   +5 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Re: "Intellectual conflicts of interest in spinal cord stimulation research - The gap between theoretical knowledge and clinical expertise". [PDF]

Interv Pain Med
Przybysz AG, Vu TN, Pisansky AJB, Schuster NM, Sheth S, Cheng DS, Lobel SM, Binler D, Duszynski B, Conger A, Schneider BJ, Mattie R.   +11 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

The disclosure of potential conflicts of interest among editors and members of editorial boards in leading ethics journals. [PDF]

Res Integr Peer Rev
Faggion CM.
europepmc   +1 more source